It has been demonstrated that in tumor-bearing immune competent mice, administration of pharmacologically optimized PEGylated kynureninase (PEG-KYNase) promoted anti-cancer effects via increases in tumor infiltration and expansion of CD8+ lymphocytes [20]. This evidence concerns the gene KYNU and cancer.